"Advancing the Fight: LAVA Therapeutics Elevates mCRPC Treatment Trial and Partners on FDA-cleared Solid Tumor Drug"

LAVA Therapeutics has made advancements in its immuno-oncology portfolio, with the lead program LAVA-1207 targeting metastatic castration-resistant prostate cancer (mCRPC) advancing to a higher dose level in phase 1/2a trials. Additionally, the company has seen progress in partnered programs, with an investigational new drug application for SGN-EGFRd2 (LAVA-1223) cleared by the FDA for advanced solid tumors. Read the full article here.